Pacific Biosciences Of California (PACB) Cash from Financing Activities (2010 - 2026)

Pacific Biosciences Of California's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 26.65% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $2.9 million (up 106.11% YoY), while the FY2025 annual figure was $3.4 million, up 107.97% from the prior year.
• Cash from Financing Activities was $1.4 million for Q1 2026 at Pacific Biosciences Of California, down from $1.5 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $196.0 million in Q1 2023 to a low of -$81.6 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged $5.4 million across 5 years, with a median of $819000.0 in 2022.
• Biggest YoY gain for Cash from Financing Activities was 3658.18% in 2023; the steepest drop was 10063.61% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $819000.0 in 2022, then sank by 10063.61% to -$81.6 million in 2023, then surged by 38.48% to -$50.2 million in 2024, then surged by 102.93% to $1.5 million in 2025, then dropped by 2.18% to $1.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $1.4 million (Q1 2026), $1.5 million (Q3 2025), and $2.0 million (Q1 2025), per Business Quant data.